Brawn Biotech Ltd
- Market Cap ₹ 6.81 Cr.
- Current Price ₹ 22.7
- High / Low ₹ 27.8 / 14.6
- Stock P/E 35.8
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | |
---|---|
0.48 | |
0.49 | |
Operating Profit | -0.01 |
OPM % | -2.08% |
0.24 | |
Interest | 0.00 |
Depreciation | 0.01 |
Profit before tax | 0.22 |
Tax % | 18.18% |
0.19 | |
EPS in Rs | 0.63 |
Dividend Payout % | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | 0% |
3 Years: | 3% |
1 Year: | 32% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | |
---|---|
Equity Capital | |
Reserves | |
Total Liabilities | |
CWIP | |
Investments | |
Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | |
---|---|
Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | |
---|---|
Debtor Days | |
Inventory Days | |
Days Payable | |
Cash Conversion Cycle | |
Working Capital Days | |
ROCE % |
Documents
Announcements
-
Board Meeting Intimation for CONSIDERING AND APPROVING THE UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30TH SEPTEMBER 2024.
7 Nov - Board meeting on 14 Nov 2024 for Q2 results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Oct - Certificate under Regulation 74(5) for Q2 2024.
-
Intimation Of Regularization Of Independent Directors
30 Sep - Regularization of two independent directors and re-appointment of a director.
-
PROCEEDINGS OF 39TH AGM -2024
30 Sep - Summary of 39th Annual General Meeting proceedings.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 30 Sep
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
Company is a fully integrated healthcare company having product registration with health and govt. institutions in India and abroad. It deals in Critical Care range of Products along with other Pharmaceutical products. Company's Pharmaceutical Formulations cover all major product segments viz. Anti-bacterial, Cardiovascular, Anti-diabetic, Analgesics, Gastrointestinal, Antifungals, Skin Care, Antipsychotics, Anti asthmatics, Antacids, Anti-malarial, and Nutritionals